CBL114F
Mouse Anti-Human IgA Antibody, clone M24A, heavy chain, FITC conjugated
clone M24A, Chemicon®, from mouse
Synonym(s):
Anti-human IgA FITC
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.46
Recommended Products
biological source
mouse
Quality Level
conjugate
FITC conjugate
antibody form
purified immunoglobulin
antibody product type
secondary antibodies
clone
M24A, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
flow cytometry: suitable
immunofluorescence: suitable
immunohistochemistry: suitable
isotype
IgG1
shipped in
wet ice
target post-translational modification
unmodified
Related Categories
Specificity
This antibody is specific for the heavy chain of human immunoglobulin A, and shows no cross-reactivity with intact human IgM or IgG, kappa or lambda light chains
Application
Immunohistological staining of IgA expressing cells in tissue sections.
Identification of surface IgA on B lymphocytes by direct Immunofluorescence.
ELISA
Flow Cytometry
Optimal working dilutions must be determined by the end user.
Identification of surface IgA on B lymphocytes by direct Immunofluorescence.
ELISA
Flow Cytometry
Optimal working dilutions must be determined by the end user.
Research Category
Secondary & Control Antibodies
Secondary & Control Antibodies
Research Sub Category
Fragment Specific Secondary Antibodies
Fragment Specific Secondary Antibodies
This Mouse anti-Human IgA Antibody, clone M24A, heavy chain, FITC conjugated is validated for use in ELISA, FC, IF, IH for the detection of Human IgA.
Physical form
The conjugate is supplied in phosphate buffered saline containing 10mM sodium azide and 1mg/ml bovine serum albumin. For flow cytometry we recommend using 10μL of conjugate per test.
Storage and Stability
Store at +4°C protected from light. DO NOT FREEZE. For long term use and storage aliquot conjugate into small volumes and store at +4°C for up to one year.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Philip A Mudd et al.
Cell, 185(4), 603-613 (2022-01-14)
SARS-CoV-2 mRNA vaccines induce robust anti-spike (S) antibody and CD4+ T cell responses. It is not yet clear whether vaccine-induced follicular helper CD4+ T (TFH) cell responses contribute to this outstanding immunogenicity. Using fine-needle aspiration of draining axillary lymph nodes from
Jackson S Turner et al.
Nature, 595(7867), 421-425 (2021-05-25)
Long-lived bone marrow plasma cells (BMPCs) are a persistent and essential source of protective antibodies1-7. Individuals who have recovered from COVID-19 have a substantially lower risk of reinfection with SARS-CoV-28-10. Nonetheless, it has been reported that levels of anti-SARS-CoV-2 serum
SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.
Alsoussi, et al.
Nature, 617, 592-598 (2023)
Jackson S Turner et al.
Nature, 596(7870), 109-113 (2021-06-29)
SARS-CoV-2 mRNA-based vaccines are about 95% effective in preventing COVID-191-5. The dynamics of antibody-secreting plasmablasts and germinal centre B cells induced by these vaccines in humans remain unclear. Here we examined antigen-specific B cell responses in peripheral blood (n = 41) and draining lymph
Joana P Bernardes et al.
Immunity, 53(6), 1296-1314 (2020-12-10)
Temporal resolution of cellular features associated with a severe COVID-19 disease trajectory is needed for understanding skewed immune responses and defining predictors of outcome. Here, we performed a longitudinal multi-omics study using a two-center cohort of 14 patients. We analyzed
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service